| Sandra Gerber, | |
|
500 Ne 1st St, Belle Glade, FL 33430-2008 | |
| (561) 261-4447 | |
| Not Available |
| Full Name | Sandra Gerber |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 500 Ne 1st St, Belle Glade, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134665375 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | RN9201122 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sandra Gerber, 500 Ne 1st St, Belle Glade, FL 33430-2008 Ph: () - | Sandra Gerber, 500 Ne 1st St, Belle Glade, FL 33430-2008 Ph: (561) 261-4447 |
News Archive
A surgical procedure aimed at bypassing a blocked artery that supplies blood to the brain did not lower the subsequent stroke rate after 2 years in people who previously had a minor stroke, compared to those who did not have the surgery.
A clinical trial of the IDEAL IMPLANT Saline-filled Breast Implant offered Teri a new "hybrid" design, combining both the natural result of silicone gel with the safety of saline for peace of mind. The trial also features a unique lump-sum payment to participants from a trust fund.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).
Researchers in the United Kingdom have conducted an extensive survey exploring the impact that lockdown had on people living with low prevalence and young-onset dementias during the first wave of the coronavirus disease 2019 (COVID-19) pandemic.
The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.
› Verified 4 days ago
Jaqui Melody Glucksman, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 306 Sw 10th St, Belle Glade, FL 33430 Phone: 561-693-5143 Fax: 561-245-9150 | |
Mrs. Kristen D'aun Lockett-putmon, APRN, FNP-C Registered Nurse Medicare: Medicare Enrolled Practice Location: 1508 Nw Avenue D Apt B2, Belle Glade, FL 33430 Phone: 561-234-8165 | |
Ms. Berkerria Nakiis Collins, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 579 Se 2nd St, Belle Glade, FL 33430 Phone: 561-631-7602 | |
Dynisha Fresneda, REGISTERED NURSE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 624 S Main St Ste 4, Belle Glade, FL 33430 Phone: 561-779-2284 | |
Mrs. Audrey G. Dorsett, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 38754 State Road 80, Belle Glade, FL 33430 Phone: 561-996-1600 Fax: 561-992-8363 | |
Mrs. Dale B Pugliese, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 38754 State Road 80, Belle Glade, FL 33430 Phone: 561-996-1600 Fax: 561-992-8363 |